AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16990605 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoSeven (recombinant factor VIIa)
Number of subjects: 48
Study 15140480 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution ultrasound
Number of subjects: 18
Study 12684362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 12684362 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 microg/kg rhvCNTF
Number of subjects: 173
Study 12684362 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microg/kg rhvCNTF
Number of subjects: 173
Study 12684362 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 microg/kg rhvCNTF
Number of subjects: 173
Study 9988955 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive management (diagnostic angiography within 2 to 3 days, followed by revascularization if indicated)
Number of subjects: 0
Study 9988955 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (radionuclide ventriculography and thallium stress testing as initial diagnostic tests)
Number of subjects: 0
Study 8583374 — intervention group
Group type: EXPERIMENTAL
Intervention: Sho‐saiko‐To
Number of subjects: 0
Study 8583374 — intervention group
Group type: EXPERIMENTAL
Intervention: Saiboku‐To
Number of subjects: 0
Study 8583374 — intervention group
Group type: EXPERIMENTAL
Intervention: Sairei‐To
Number of subjects: 0
Study 2182241 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 U of anistreplase (APSAC)
Number of subjects: 156
Study 535405 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 0
Study 535405 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 100 mg
Number of subjects: 0
Study 31673898 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib in combination with lenalidomide and dexamethasone (KRd)
Number of subjects: 0
Study 31673898 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 0
Study 30109404 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-ml autologous adipose-derived stromal vascular fraction (SVF) treatment
Number of subjects: 16
Study 30109404 — intervention group
Group type: COMPARATOR
Intervention: 4-ml hyaluronic acid treatment
Number of subjects: 16
Study 30109404 — intervention group
Group type: EXPERIMENTAL
Intervention: SVF treatment
Number of subjects: 16
Study 29066605 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic exams (E)
Number of subjects: 145
Study 29066605 — intervention group
Group type: COMPARATOR
Intervention: Paper exams (P)
Number of subjects: 145
Study 26381201 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 145
Study 26381201 — intervention group
Group type: COMPARATOR
Intervention: Microflare only
Number of subjects: 145
Study 24800919 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine liquid formulation
Number of subjects: 20
Study 24800919 — intervention group
Group type: COMPARATOR
Intervention: 6-mercaptopurine capsules
Number of subjects: 20
Study 21431414 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined peer and managerial intervention
Number of subjects: 1382
Study 21431414 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education
Number of subjects: 1382
Study 21431414 — intervention group
Group type: EXPERIMENTAL
Intervention: Managerial training
Number of subjects: 1382
Study 21431414 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 1382
Study 21431414 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishments with condom use rules
Number of subjects: 1382
Study 18751689 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily (40QD)
Number of subjects: 3
Study 18751689 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily (20TD)
Number of subjects: 3
Study 18751689 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg 4 times daily (10Q4D)
Number of subjects: 3
Study 18751689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 17900462 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid arterial intima‐medial thickness (IMT)
Number of subjects: 315
Study 17900462 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortofemoral pulse wave velocity (PWV[a‐f])
Number of subjects: 315
Study 17900462 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic arterial compliance (SAC)
Number of subjects: 315
Study 17900462 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid‐derived augmentation index
Number of subjects: 315
Study 15006018 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol adjustable maintenance dosing (AMD)
Number of subjects: 658
Study 15006018 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol AMD
Number of subjects: 658
Study 15006018 — intervention group
Group type: COMPARATOR
Intervention: budesonide/formoterol FD
Number of subjects: 658
Study 15006018 — intervention group
Group type: COMPARATOR
Intervention: salmeterol/fluticasone FD
Number of subjects: 658
Study 11148482 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 8
Study 11148482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9671904 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein ligation first
Number of subjects: 46
Study 9671904 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery ligation first
Number of subjects: 46
Study 9671904 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects and patients with interstitial pulmonary fibrosis)
Number of subjects: 46
Study 9671904 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-cell lung cancer patients
Number of subjects: 46
Study 8030598 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet devoid of proline (group 1)
Number of subjects: 20
Study 8030598 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet devoid of proline, arginine, aspartate, glutamate, and serine (group 2)
Number of subjects: 20
Study 8030598 — intervention group
Group type: COMPARATOR
Intervention: Complete L-amino acid mixture diet (group 3)
Number of subjects: 20
Study 31407937 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning to BREATHE (L2B)
Number of subjects: 111
Study 31407937 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Therapy‐Adolescent Skills Training
Number of subjects: 111
Study 31407937 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for L2B
Number of subjects: 111
Study 31407937 — intervention group
Group type: COMPARATOR
Intervention: Preference condition (preference vs. random)
Number of subjects: 111
Study 31407937 — intervention group
Group type: COMPARATOR
Intervention: Baseline program preference
Number of subjects: 111
Study 31508704 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive with laser etching
Number of subjects: 84
Study 31508704 — intervention group
Group type: COMPARATOR
Intervention: Transbond XT with acid etching
Number of subjects: 84
Study 31508704 — intervention group
Group type: COMPARATOR
Intervention: Transbond XT with laser etching
Number of subjects: 84
Study 31508704 — intervention group
Group type: COMPARATOR
Intervention: Universal adhesive in self-etch mode
Number of subjects: 84
Study 31508704 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive with acid etching (5, 10, 15 s)
Number of subjects: 84
Study 31508704 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive with three different etching times
Number of subjects: 84
Study 28225835 — intervention group
Group type: EXPERIMENTAL
Intervention: Half dose of mulberry-extract (Reducose)
Number of subjects: 37
Study 28225835 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal dose of mulberry-extract (Reducose)
Number of subjects: 37
Study 28225835 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of mulberry-extract (Reducose)
Number of subjects: 37
Study 28225835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 26436182 — intervention group
Group type: COMPARATOR
Intervention: Proximity to alcohol outlets for drinkers (0.18 +/- 0.15 miles)
Number of subjects: 166
Study 26436182 — intervention group
Group type: COMPARATOR
Intervention: Density of alcohol outlets within a 1-mile radius for drinkers (153 +/- 47)
Number of subjects: 166
Study 26436182 — intervention group
Group type: COMPARATOR
Intervention: Number of alcohol outlets at distances of 0.10-0.25 miles for drinkers (19 +/- 19)
Number of subjects: 166
Study 26436182 — intervention group
Group type: COMPARATOR
Intervention: Number of alcohol outlets at distances of 0.25-0.50 miles for drinkers (43 +/- 25)
Number of subjects: 166
Study 26436182 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity and density of alcohol outlets
Number of subjects: 166
Study 25072523 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong (Chaoyi Fanhuan qigong [CFQ]) practiced 45 min/day for 8 weeks
Number of subjects: 73
Study 25072523 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong (level 2 CFQ) in extension trial
Number of subjects: 73
Study 25072523 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong (initial 8 weeks)
Number of subjects: 73
Study 25072523 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong (narratives from RCT)
Number of subjects: 73
Study 21947819 — intervention group
Group type: EXPERIMENTAL
Intervention: Abolition centralization, reduction centralization, unstable centralization
Number of subjects: 176
Study 21947819 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheralization
Number of subjects: 176
Study 21947819 — intervention group
Group type: EXPERIMENTAL
Intervention: No effect
Number of subjects: 176
Study 21947819 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralization groups (abolition, reduction, unstable)
Number of subjects: 176
Study 21947819 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralization and peripheralization
Number of subjects: 176
Study 19306199 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet version of SF-36
Number of subjects: 782
Study 19306199 — intervention group
Group type: COMPARATOR
Intervention: Pen-and-paper version of SF-36
Number of subjects: 782
Study 16884135 — intervention group
Group type: EXPERIMENTAL
Intervention: PNP (Pediatric Nurse Practitioners)
Number of subjects: 65
Study 16884135 — intervention group
Group type: COMPARATOR
Intervention: Resident care
Number of subjects: 65
Study 15256423 — intervention group
Group type: EXPERIMENTAL
Intervention: Early allogeneic bone marrow transplantation (alloBMT) after 2 consolidation courses
Number of subjects: 198
Study 15256423 — intervention group
Group type: COMPARATOR
Intervention: Delayed unpurged autologous stem cell transplantation (ASCT) after 1 additional reinduction
Number of subjects: 198
Study 15256423 — intervention group
Group type: COMPARATOR
Intervention: Randomized interferon-alpha maintenance
Number of subjects: 198
Study 11387538 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches
Number of subjects: 3575
Study 9281301 — intervention group
Group type: EXPERIMENTAL
Intervention: New isosorbide dinitrate tablet formulation (5 mg)
Number of subjects: 18
Study 9281301 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation of isosorbide dinitrate
Number of subjects: 18
Study 8103611 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sotalol treatment (pre- and postoperative)
Number of subjects: 101
Study 8103611 — intervention group
Group type: COMPARATOR
Intervention: Routine beta-blocking treatment (half the preoperative dose)
Number of subjects: 101
Study 3029592 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial radiotherapy plus chemotherapy
Number of subjects: 399
Study 3029592 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed radiotherapy plus chemotherapy
Number of subjects: 399
Study 3029592 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 399
Study 30737932 — intervention group
Group type: EXPERIMENTAL
Intervention: Endodontic treatment with good quality root filling and good quality crown restoration (GE + GR)
Number of subjects: 1001
Study 30737932 — intervention group
Group type: EXPERIMENTAL
Intervention: Endodontic treatment with good quality root filling and poor quality crown restoration (GE + PR)
Number of subjects: 1001
Study 30737932 — intervention group
Group type: EXPERIMENTAL
Intervention: Endodontic treatment with poor quality root filling and good quality crown restoration (PE + GR)
Number of subjects: 1001
Study 30737932 — intervention group
Group type: EXPERIMENTAL
Intervention: Endodontic treatment with poor quality root filling and poor quality crown restoration (PE + PR)
Number of subjects: 1001
Study 30737932 — intervention group
Group type: EXPERIMENTAL
Intervention: Endodontic treatment with root posts
Number of subjects: 1001
Study 30737932 — intervention group
Group type: EXPERIMENTAL
Intervention: Endodontic treatment without root posts
Number of subjects: 1001
Study 27113485 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐00489791 (20 mg)
Number of subjects: 256
Study 27113485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 24168514 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral isotretinoin (ISO), 20 mg/day for six months
Number of subjects: 24
Study 24168514 — intervention group
Group type: COMPARATOR
Intervention: 0.05% topical retinoic acid (RA) cream for six months
Number of subjects: 24
Study 22123685 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r)
Number of subjects: 445
Study 22123685 — intervention group
Group type: COMPARATOR
Intervention: nevirapine (NVP)
Number of subjects: 445
Study 20695687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 74
Study 20695687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 18343261 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 728
Study 18343261 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 728
Study 18343261 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Number of subjects: 728
Study 18343261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 728
Study 16299878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing at 60 min postpartum (n = 126)
Number of subjects: 249
Study 16299878 — intervention group
Group type: COMPARATOR
Intervention: No bathing (n = 123)
Number of subjects: 249
Study 12572927 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg of intravenous L-carnitine at the end of each hemodialysis treatment (Group A)
Number of subjects: 53
Study 12572927 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 53
Study 10601747 — intervention group
Group type: EXPERIMENTAL
Intervention: Discourse-dependent semantic anomalies (e.g., 'slow')
Number of subjects: 0
Study 10601747 — intervention group
Group type: COMPARATOR
Intervention: Coherent control words (e.g., 'quick')
Number of subjects: 0
Study 10601747 — intervention group
Group type: EXPERIMENTAL
Intervention: Anomalous words in single sentences
Number of subjects: 0
Study 10601747 — intervention group
Group type: EXPERIMENTAL
Intervention: Words previously anomalous in discourse
Number of subjects: 0
Study 8521118 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated patients with DH
Number of subjects: 10
Study 8521118 — intervention group
Group type: COMPARATOR
Intervention: Patients with DH on a long-term GFD
Number of subjects: 10
Study 8521118 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated patients with DH after adhering to GFD for 3 months
Number of subjects: 10
Study 8521118 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects on an ordinary diet
Number of subjects: 10
Study 1824560 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 1034
Study 1824560 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + methotrexate + 5-fluorouracil
Number of subjects: 1034
Study 1824560 — intervention group
Group type: COMPARATOR
Intervention: No systemic treatment
Number of subjects: 1034
Study 7025639 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptothermal method
Number of subjects: 0
Study 7025639 — intervention group
Group type: COMPARATOR
Intervention: Ovulation method
Number of subjects: 0
Study 30969260 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa (daily subcutaneous injections)
Number of subjects: 7
Study 30969260 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 7
Study 29716784 — intervention group
Group type: EXPERIMENTAL
Intervention: Emixustat 2.5 mg
Number of subjects: 508
Study 29716784 — intervention group
Group type: EXPERIMENTAL
Intervention: Emixustat 5 mg
Number of subjects: 508
Study 29716784 — intervention group
Group type: EXPERIMENTAL
Intervention: Emixustat 10 mg
Number of subjects: 508
Study 29716784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508
Study 29716784 — intervention group
Group type: EXPERIMENTAL
Intervention: Emixustat (all doses combined)
Number of subjects: 508
Study 29716784 — intervention group
Group type: EXPERIMENTAL
Intervention: Emixustat
Number of subjects: 508
Study 26360658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Picosulphate (NaPico)
Number of subjects: 72
Study 26360658 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene Glycol (PEG)
Number of subjects: 72
Study 24249695 — intervention group
Group type: EXPERIMENTAL
Intervention: Early frenotomy intervention group
Number of subjects: 107
Study 24249695 — intervention group
Group type: COMPARATOR
Intervention: Standard care comparison group
Number of subjects: 107
Study 22353582 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst TENS
Number of subjects: 0
Study 22353582 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 0
Study 19641360 — intervention group
Group type: EXPERIMENTAL
Intervention: TURIS (transurethral resection in saline)
Number of subjects: 40
Study 19641360 — intervention group
Group type: COMPARATOR
Intervention: TURP (traditional monopolar resection)
Number of subjects: 40
Study 17469136 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement of beta1 integrin on T cells from patients with active SLE
Number of subjects: 0
Study 17469136 — intervention group
Group type: COMPARATOR
Intervention: Transfection of dominant-negative truncations of FAK or WT PTEN
Number of subjects: 0
Study 15503656 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-588 (Pfizer)
Number of subjects: 0
Study 11521333 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic electrical conversion
Number of subjects: 0
Study 11521333 — intervention group
Group type: COMPARATOR
Intervention: Monophasic electrical conversion
Number of subjects: 0
Study 9394172 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus exposure to pulsed magnetic fields (PMF) for four weeks (sinusoidal form, 0.95 to 1.05 Hz, amplitude +/- 2400 nano Teslas)
Number of subjects: 20
Study 9394172 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 20
Study 9394172 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus exposure to pulsed magnetic fields (PMF)
Number of subjects: 20
Study 7515300 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF at a daily dose of 50 micrograms/m2 subcutaneously
Number of subjects: 20
Study 7515300 — intervention group
Group type: COMPARATOR
Intervention: No G‐CSF (Control)
Number of subjects: 20
Study 7515300 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 20
Study 2895435 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (greater than 2 mg lorazepam equivalents daily)
Number of subjects: 17
Study 2895435 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepines (less than 2 mg lorazepam equivalents daily)
Number of subjects: 17
Study 31665874 — intervention group
Group type: COMPARATOR
Intervention: Supervised training
Number of subjects: 17
Study 31665874 — intervention group
Group type: COMPARATOR
Intervention: Home-based training
Number of subjects: 17
Study 31665874 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sample (both groups)
Number of subjects: 17
Study 29411716 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored zirconia (A3)
Number of subjects: 72
Study 29411716 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored zirconia (D4)
Number of subjects: 72
Study 29411716 — intervention group
Group type: COMPARATOR
Intervention: Control (non-colored zirconia)
Number of subjects: 72
Study 26921523 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and Caring for infants with special needs (COPCA)
Number of subjects: 46
Study 26921523 — intervention group
Group type: COMPARATOR
Intervention: Traditional Infant Physiotherapy (TIP)
Number of subjects: 46
Study 25117466 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week aerobic training
Number of subjects: 9
Study 25117466 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-training)
Number of subjects: 9
Study 22978771 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (750 mg/day)
Number of subjects: 119
Study 22978771 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (4 mg/day)
Number of subjects: 119
Study 20162509 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid for 3 weeks (n = 20)
Number of subjects: 40
Study 20162509 — intervention group
Group type: COMPARATOR
Intervention: No treatment for 3 weeks (n = 20)
Number of subjects: 40
Study 20162509 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women with euthyroid status)
Number of subjects: 40
Study 18019394 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein products for renal patients (LPP)
Number of subjects: 6
Study 18019394 — intervention group
Group type: COMPARATOR
Intervention: Free low-protein diet (NO-LPP)
Number of subjects: 6
Study 16142551 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release oxybutynin chloride 10 mg/day
Number of subjects: 790
Study 16142551 — intervention group
Group type: COMPARATOR
Intervention: Extended-release tolterodine tartrate 4 mg/day
Number of subjects: 790
Study 12905664 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 10484220 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 25
Study 10484220 — intervention group
Group type: COMPARATOR
Intervention: Weight-bearing position
Number of subjects: 25